Maynard Um
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Biogen (BIIB)
-
-
-
-
-
-
-
Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s
-
-
-
-
-
-
-
Biogen (BIIB) PT Lowered to $200 at Bernstein SocGen Group
-
-
-
-
-
-
-
UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts
-
-
-
-
-
-
-
William Blair on Biogen (BIIB): 'we see potential to add $1.54 billion in sales' through APLS deal
-
-
-
-
-
-
-
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion or $41/sh plus CVR
-
-
-
-
-
-
-
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
-
406,203 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

